Mohr Davidow Ventures Joins Industry Leaders in Honoring Genetic Alliance's 25 Years of Service

Firm honors life science innovators, scientists and clinicians committed to transforming health through genetics

Sep 22, 2011, 13:33 ET from Mohr Davidow

MENLO PARK, Calif. and WASHINGTON, Sept. 22, 2011 /PRNewswire/ -- For 25 years, Genetic Alliance has dedicated the focus of its work on genetics advocacy programs supporting the health of individuals, families, and communities. Mohr Davidow, a leading early stage Silicon Valley venture capital firm, is pleased to announce its support of the organization and its 25th Anniversary celebration, which culminates at a gala event this evening at the National Geographic Museum in Washington, D.C.


"Genetic Alliance has transformed the public perception of genetics by dissolving boundaries and fostering dialogue among all the critical stakeholders across industry, academia, government and the public," said Sue Siegel, General Partner at Mohr Davidow. "We are very proud of our partnership with Genetic Alliance and delighted to support their 25 years as the voice of advocacy in genetics."

Participants of the event will celebrate "25 Years of Innovation" surrounded by a museum-quality Innovators Exhibit honoring individuals from the genetics, health, and advocacy community. They will also preview a new video interview series capturing perspectives on innovation from genetics luminaries such as Gene Early, Stephen Friend, Alan Guttmacher, Eric Lander and James Watson. The Innovator Series was produced with support from Mohr Davidow and can be viewed online at:

"We are grateful for Mohr Davidow's commitment to our work and the communities that we serve," said Sharon Terry, Genetic Alliance President and CEO. "We appreciate the many contributions they have made to funding and advancing innovations that are dramatically changing our understanding of how genetics affect human health and disease."

To learn more about the organization and its 25th Anniversary celebration, please visit

About Mohr Davidow

For more than 25 years, the Mohr Davidow team has invested in early stage startups and worked closely with exceptional entrepreneurs to create venture returns by developing and bringing to market new, technology-based ideas, products and services. The firm invests in companies that transform industries whether through better infrastructure for our rapidly evolving data-intensive digital world, more efficient power for our planet, or better, more personalized medicine. Category-leading companies funded by Mohr Davidow include: Agile (ORCL); Brocade (BRDC); Genomatica; HealthTap; Kabbage; Nanosolar; nLight; ONI Systems (CIEN); Pacific Biosciences (PACB); Panasas; ParAllele (AFFX); Personalis; Proofpoint; OPXBIO; RainDance Technologies; Rally Software; Rambus (RMBS); Recurrent Energy (acquired by Sharp Corporation); Sequenta; Shutterfly (SFLY); Tethys Bioscience; Ticketfly; Verinata Health; and ZeaChem. The firm has $1.85 billion under management. For more information, visit

SOURCE Mohr Davidow